The effect of capsule composition in the reversal of hyperglycemia in diabetic mice transplanted with microencapsulated allogeneic islets.

Abstract:

:The transplantation of microencapsulated islets may allow reversal of hyperglycemia in the absence of immunosuppression. Poly-L-lysine (PLL) on capsules may potentiate the fibrotic reaction against implanted capsules. The aims of this study were to investigate how the biocompatibility of such capsules affects their function in vivo and to compare their efficacy relative to naked islets after intraperitoneal transplantation to nude or immune competent mice. Alloxan-diabetic C57BL/6 wild-type or nude (nu/nu) mice were transplanted with naked BALB/c islets, empty capsules, or microencapsulated BALB/c islets. Three types of capsules were used, one containing a high guluronic acid (G) alginate and PLL, one with a high mannuronic acid (M) alginate and PLL, and one high M alginate capsule with no PLL. Hyperglycemia in nude mice was reversed after transplantation of naked islets or islets encapsulated in a capsule containing high M alginate. Nude mice transplanted with islets encapsulated in the high G capsules showed only a transient reversal of hyperglycemia. In an allogeneic system, naked BALB/c islets were rejected by day 10 after transplantation, whereas the islets encapsulated in high M capsules continued to function for at least a month. When PLL was excluded from the capsules, the grafts functioned for up to 8 weeks. Islets microencapsulated in high G alginate capsules fail to reverse hyperglycemia for more than a few days in nude mice. However, islets in high M alginate capsules can reverse hyperglycemia in nude and immune competent mice. Islets microencapsulated in PLL-free high M alginate capsules function for 8 weeks in immune competent mice.

journal_name

Diabetes Technol Ther

authors

King A,Lau J,Nordin A,Sandler S,Andersson A

doi

10.1089/152091503322250677

keywords:

subject

Has Abstract

pub_date

2003-01-01 00:00:00

pages

653-63

issue

4

eissn

1520-9156

issn

1557-8593

journal_volume

5

pub_type

杂志文章
  • Continuous glucose monitoring health outcomes.

    abstract::Continuous glucose monitoring (CGM) is a new tool that has recently become available to people with diabetes. Properly designing and conducting trials in order to answer important questions regarding the clinical usefulness of CGM is very difficult and fraught with many confounding variables and unique challenges. Ini...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2009.0012

    authors: Edelman SV,Bailey TS

    更新日期:2009-06-01 00:00:00

  • The effect of local subcutaneous delivery of vascular endothelial growth factor on the function of a chronically implanted amperometric glucose sensor.

    abstract::The foreign body capsule that forms around implanted devices such as glucose sensors is hypovascular and has limited permeability to glucose. Such a capsule may function better if well vascularized. We hypothesized that capsular vascularization achieved by local release of vascular endothelial growth factor (VEGF) wou...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/152091504773731320

    authors: Ward WK,Wood MD,Casey HM,Quinn MJ,Federiuk IF

    更新日期:2004-04-01 00:00:00

  • Role of chronic and acute hyperglycemia in the development of diabetes complications.

    abstract::Chronic hyperglycemia, as assessed by hemoglobin A1c (HbA1c) levels, has been associated with the development of microvascular and macrovascular complications of diabetes. Several studies have shown that acute hyperglycemia can add to the effect of chronic hyperglycemia in inducing tissue damage. Acute hyperglycemia c...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2010.0146

    authors: Marcovecchio ML,Lucantoni M,Chiarelli F

    更新日期:2011-03-01 00:00:00

  • Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes.

    abstract::Type 2 diabetes is thought to develop as a result of progressive beta-cell dysfunction in the setting of insulin resistance, leading to increased risks of microvascular and macrovascular complications. Type 2 diabetes is currently treated with diet and exercise, followed by oral drug therapy, and finally exogenous ins...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2006.8.385

    authors: Kendall DM,Kim D,Maggs D

    更新日期:2006-06-01 00:00:00

  • Clinical studies on chromium picolinate supplementation in diabetes mellitus--a review.

    abstract::Chromium (Cr) picolinate (CrPic) is a widely used nutritional supplement for optimal insulin function. A relationship among Cr status, diabetes, and associated pathologies has been established. Virtually all trials using CrPic supplementation for subjects with diabetes have demonstrated beneficial effects. Thirteen of...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2006.8.677

    authors: Broadhurst CL,Domenico P

    更新日期:2006-12-01 00:00:00

  • Development and Validation of the Continuous Subcutaneous Insulin Infusion-Related Quality-of-Life (CSII-QOL) Scale.

    abstract:: Background: Continuous subcutaneous insulin infusion (CSII) is associated with improved glycemic control, a reduced incidence of hypoglycemia, and improved quality of life (QOL). To date, however, there has been no QOL scale specific to CSII. The objective of this study wa...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0216

    authors: Sakane N,Murata T,Tone A,Kato K,Kimura M,Kawashima S,Sawaki H,Hirota Y,Okada A,Kuroda A,Matsuhisa M,Watanabe T,Suganuma A,Nirengi S,Toyoda M

    更新日期:2020-03-01 00:00:00

  • What we can really expect from telemedicine in intensive diabetes treatment: results from 3-year study on type 1 pregnant diabetic women.

    abstract::Existing standards of the management of the diabetic patients are not efficient enough, and further improvement is needed. The major objective of this paper is to present and discuss the therapeutic effectiveness of an intensive care telematic system designed and applied for intensive treatment of pregnant type 1 diab...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1089/15209150152811207

    authors: Wojcicki JM,Ladyzynski P,Krzymien J,Jozwicka E,Blachowicz J,Janczewska E,Czajkowski K,Karnafel W

    更新日期:2001-01-01 00:00:00

  • Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.

    abstract:OBJECTIVE:To evaluate the safety of in-home use of the MiniMed™ 670G system with SmartGuard™ technology in children with type 1 diabetes (T1D). METHODS:Participants (N = 105, ages 7-13 years, mean age 10.8 ± 1.8 years) were enrolled at nine centers (eight in the United States and one in Israel) and completed a 2-week ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2018.0264

    authors: Forlenza GP,Pinhas-Hamiel O,Liljenquist DR,Shulman DI,Bailey TS,Bode BW,Wood MA,Buckingham BA,Kaiserman KB,Shin J,Huang S,Lee SW,Kaufman FR

    更新日期:2019-01-01 00:00:00

  • High glycemic variability assessed by continuous glucose monitoring after surgical treatment of obesity by gastric bypass.

    abstract:BACKGROUND:Obesity surgery elicits complex changes in glucose metabolism that are difficult to observe with discontinuous glucose measurements. We aimed to evaluate glucose variability after gastric bypass by continuous glucose monitoring (CGM) in a real-life setting. METHODS:CGM was performed for 4.2 ± 1.3 days in th...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2010.0203

    authors: Hanaire H,Bertrand M,Guerci B,Anduze Y,Guillaume E,Ritz P

    更新日期:2011-06-01 00:00:00

  • Is angiotensin I-converting enzyme a "master" disease gene?

    abstract::Clustering of diseases has been appreciated by health insurers and epidemiologists for some time. Co-morbidity suggests shared pathways of disease. It is by now well agreed that common diseases have a strong genetic component. Here we present evidence that the angiotensin I-converting enzyme (ACE) deletion/deletion (D...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/152091502320798321

    authors: Moskowitz DW

    更新日期:2002-01-01 00:00:00

  • Accuracy of continuous glucose monitoring during exercise in type 1 diabetes pregnancy.

    abstract:BACKGROUND:Performance of continuous glucose monitors (CGMs) may be lower when glucose levels are changing rapidly, such as occurs during physical activity. Our aim was to evaluate accuracy of a current-generation CGM during moderate-intensity exercise in type 1 diabetes (T1D) pregnancy. SUBJECTS AND METHODS:As part o...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2012.0292

    authors: Kumareswaran K,Elleri D,Allen JM,Caldwell K,Nodale M,Wilinska ME,Amiel SA,Hovorka R,Murphy HR

    更新日期:2013-03-01 00:00:00

  • Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist.

    abstract::Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are highly effective at lowering hemoglobin A1c (HbA1c) and facilitating weight loss. Four agents in the GLP-1 RA class, albiglutide, liraglutide, dulaglutide, and semaglutide, also have cardioprotective effects. However, subcutaneous administration of these agents...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2019.0185

    authors: Bucheit JD,Pamulapati LG,Carter N,Malloy K,Dixon DL,Sisson EM

    更新日期:2020-01-01 00:00:00

  • Assessment of a new insulin preparation for implanted pumps used in the treatment of type 1 diabetes.

    abstract:BACKGROUND:Implanted insulin pumps using the peritoneal route provide long-term improvement of glucose control compared with subcutaneous insulin therapy in type 1 diabetes (T1D) patients. The stability of insulin preparation is critical for a safe use in implanted pumps. Insuman implantable(®) (400 IU/mL) (Sanofi-Aven...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2013.0369

    authors: Schaepelynck P,Riveline JP,Renard E,Hanaire H,Guerci B,Baillot-Rudoni S,Sola-Gazagnes A,Catargi B,Fontaine P,Millot L,Martin JF,Tachouaft H,Jeandidier N,EVADIAC Group.

    更新日期:2014-09-01 00:00:00

  • Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen.

    abstract:: Background: This observational study investigated whether the connected NovoPen® 6 could influence insulin regimen management and glycemic control in people with type 1 diabetes (T1D) using a basal-bolus insulin regimen and continuous glucose monitoring in a real-world set...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0411

    authors: Adolfsson P,Hartvig NV,Kaas A,Møller JB,Hellman J

    更新日期:2020-10-01 00:00:00

  • A new imaging and data transmitting device for telemonitoring of diabetic foot syndrome patients.

    abstract:BACKGROUND:Proper healing of ulcers and wounds on the feet of diabetes patients is important in order to prevent amputation. If the wound area reduction during the first 4 weeks of the treatment is not 40% or more, reevaluation of the treatment is necessary. The wound area evaluation is not complicated when the patient...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2011.0004

    authors: Foltynski P,Ladyzynski P,Migalska-Musial K,Sabalinska S,Ciechanowska A,Wojcicki J

    更新日期:2011-08-01 00:00:00

  • Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses.

    abstract:: Background: The Medtronic MiniMed™ 670G system adjusts basal insulin delivery in response to continuous glucose monitoring levels and is already in use in clinical practice. We tested the home-based feasibility of the new MiniMed advanced hybrid closed-loop (AHCL) system, ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2020.0448

    authors: Nimri R,Grosman B,Roy A,Nir J,Fisch Shvalb N,Kurtz N,Loewenthal N,Gillon-Keren M,Muller I,Atlas E,Phillip M

    更新日期:2020-12-08 00:00:00

  • "Glucometrics"--assessing the quality of inpatient glucose management.

    abstract:BACKGROUND:For patients with diabetes, the quality of outpatient glycemic control is readily assessed by hemoglobin A1c. In contrast, standardized measures for assessing the quality of blood glucose (BG) management in hospitalized patients are lacking. Because of recent studies demonstrating the benefits of strict glyc...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2006.8.560

    authors: Goldberg PA,Bozzo JE,Thomas PG,Mesmer MM,Sakharova OV,Radford MJ,Inzucchi SE

    更新日期:2006-10-01 00:00:00

  • A Feasibility Study of Paired Continuous Glucose Monitoring Intrapartum and in the Newborn in Pregnancies Complicated by Type 1 Diabetes.

    abstract:AIM:To describe the continuous glucose monitoring (CGM) profiles of type 1 diabetes (T1D) offspring in the early neonatal period and its association with maternal intrapartum glucose control. METHODS:A prospective observational study of T1D pregnant women and their neonatal offspring. Women had a CGM sensor inserted 2...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2018.0221

    authors: Stewart ZA,Thomson L,Murphy HR,Beardsall K

    更新日期:2019-01-01 00:00:00

  • High Glucose Variability in Hospitalized Patients with Type 1 Diabetes Mellitus.

    abstract:BACKGROUND:Glucose variability (GV) has been increasingly (or more extensively) studied in patients with type 1 diabetes (T1D) in the ambulatory setting; limited data exist on GV in hospitalized patients with T1D. MATERIALS AND METHODS:Retrospective single center cohort study, we analyzed in-hospital glucose measureme...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2017.0107

    authors: Dadlani V,Tamhane SU,Sun A,Sharma A,Delivanis DA,Thapa P,Carter RE,Kudva YC

    更新日期:2017-10-01 00:00:00

  • Continuous glucose monitoring in patients undergoing cardiac surgery.

    abstract:OBJECTIVES:Hyperglycemia is a prominent feature among patients exposed to major stress such as in cardiac surgery. The implementation of a continuous glucose monitoring system (CGMS) for glucose monitoring during cardiac surgery was assessed. SUBJECTS AND METHODS:Fifty-nine consecutive patients who underwent cardiac s...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2011.0154

    authors: Kalmovich B,Bar-Dayan Y,Boaz M,Wainstein J

    更新日期:2012-03-01 00:00:00

  • The use of continuous glucose monitoring in patients with type 2 diabetes.

    abstract::Since the late 1970s, self-monitoring of blood glucose has been the standard for assessing daily glycemic control. The first continuous glucose monitor became available in 1999. Numerous clinical trials have documented the benefits of continuous glucose monitoring (CGM) in patients with type 1 diabetes mellitus (DM). ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2011.0086

    authors: Meade LT

    更新日期:2012-02-01 00:00:00

  • Evaluation of Blood Glucose Meter Efficacy in an Antenatal Diabetes Clinic.

    abstract:BACKGROUND:The optimal treatment of diabetes in pregnancy requires accurate measurement of blood glucose levels, in order to minimize adverse outcomes for both mother and neonate. Self-monitoring of blood glucose is routinely used to measure glycemic control and to assess whether treatment targets are being met; howeve...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,收录出版

    doi:10.1089/dia.2015.0104

    authors: McGrath RT,Donnelly VC,Glastras SJ,Preda VA,Sheriff N,Ward P,Hocking SL,Fulcher GR

    更新日期:2016-02-01 00:00:00

  • Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.

    abstract:BACKGROUND:SAR342434 is a biosimilar follow-on of insulin lispro-Humalog®. This study aimed to show similar efficacy, safety, and immunogenicity of SAR342434 (SAR-Lis) versus insulin lispro-Humalog (Ly-Lis) in adult patients with type 1 diabetes (T1DM) treated with multiple daily injections while using basal insulin gl...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2017.0117

    authors: Garg SK,Wernicke-Panten K,Rojeski M,Pierre S,Kirchhein Y,Jedynasty K

    更新日期:2017-09-01 00:00:00

  • Fluorescein kinetics in interstitial fluid harvested from diabetic skin during fluorescein angiography: implications for glucose monitoring.

    abstract:BACKGROUND:Glucose monitoring based on sampling skin interstitial fluid (ISF) is being developed as an alternative to fingerstick blood glucose monitoring. Time delays between rapidly changing levels of glucose in blood and interstitial fluid have been reported in the literature to be between 5 and 20 minutes. This stu...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/152091599317530

    authors: Smith A,Yang D,Delcher H,Eppstein J,Williams D,Wilkes S

    更新日期:1999-04-01 00:00:00

  • Where Do We Stand with Closed-Loop Systems and Their Challenges?

    abstract::Treatments for type 1 diabetes have advanced significantly over recent years. There are now multiple hybrid closed-loop systems commercially available and additional systems are in development. Challenges remain, however. This review outlines the recent advances in closed-loop systems and outlines the remaining challe...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0469

    authors: Jackson M,Castle JR

    更新日期:2020-07-01 00:00:00

  • Overcoming skin's barrier: the search for effective and user-friendly drug delivery.

    abstract::Although hypodermic needles rapidly deliver large doses of drugs such as insulin across the skin for systemic administration, the pain, local trauma, and difficulty to achieve sustained or complex delivery profiles has motivated development of novel alternative technologies. Microneedles, jet injectors, and thermal po...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/152091501300209606

    authors: Prausnitz MR

    更新日期:2001-07-01 00:00:00

  • Resistance to Data Loss of Glycemic Variability Measurements in Long-Term Continuous Glucose Monitoring.

    abstract:: Background: Continuous glucose monitoring (CGM) is a method of estimating blood glucose values from those recorded in the interstitial fluid. Because increasingly longer CGM measurements are possible, errors and data loss become more and more likely and potentially more da...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2018.0247

    authors: Kucharski P,Pagacz K,Szadkowska A,Młynarski W,Romanowski A,Fendler W

    更新日期:2018-12-01 00:00:00

  • Metrics to Evaluate Quality of Glycemic Control: Comparison of Time in Target, Hypoglycemic, and Hyperglycemic Ranges with "Risk Indices".

    abstract:OBJECTIVE:We sought to cross validate several metrics for quality of glycemic control, hypoglycemia, and hyperglycemia. RESEARCH DESIGN AND METHODS:We analyzed the mathematical properties of several metrics for overall glycemic control, and for hypo- and hyperglycemia, to evaluate their similarities, differences, and ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2017.0416

    authors: Rodbard D

    更新日期:2018-05-01 00:00:00

  • Person-centered Web support to women with type 1 diabetes in pregnancy and early motherhood--the development process.

    abstract:BACKGROUND:Pregnancy and early motherhood are extraordinarily demanding periods for women with type 1 diabetes, who therefore need optimal support. This article describes the process of developing person-centered Web-based support for women with type 1 diabetes during the period of pregnancy through early motherhood. I...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2012.0217

    authors: Berg M,Adolfsson A,Ranerup A,Sparud-Lundin C,University of Gothenburg Centre for Person-Centred Care.

    更新日期:2013-01-01 00:00:00

  • Frequency of the dawn phenomenon in type 2 diabetes: implications for diabetes therapy.

    abstract::This study was designed to assess the frequency of the dawn phenomenon in patients with type 2 diabetes. A secondary aim was to examine the influence of varying treatment regimens on the frequency of the dawn phenomenon. The dawn phenomenon was defined as a rise in plasma glucose levels of > or = 0.5 mmol/L (10 mg/dL)...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1089/152091502320798213

    authors: Carroll MF,Hardy KJ,Burge MR,Schade DS

    更新日期:2002-01-01 00:00:00